fate therapeutics stock price target

Wall Street is positive on Fate Therapeutics Inc FATE. Forecast target price for 05-03-2022.

Fate Therapeutics Now The Least Expensive Vs Binance Coin This Year Nasdaq

Stock Price Forecast.

. Fate Therapeutics Inc FATE stock is trading at 5352 as of 225 PM on Wednesday Nov 17 a loss of -197 or -355 from the previous closing price of 5549. In terms of how Fate Therapeutics Inc. Fate Therapeutics reported interim results from 14 patients treated with FT596 an off-the-shelf immunotherapy made of natural killer cells engineered to target CD19.

The Company is focused on the development of programmed cellular. In comparison to the median Healthcare stock FATEs pricesales ratio is 11793 higher now standing at 1452. Is 3589 for 2023 Mar.

The 20 analysts offering price forecasts for Fate Therapeutics have a median target of 9395 with a high estimate of 13000 and a low estimate of 4000. Based On Fundamental Analysis. May 6 2022 308 pm.

Ad Our Strong Buys Double the SP. Ad When you sign up youll reveal the names and ticker symbols of these 5 companies. Nasdaq REAL TIME 327 PM EDT 051222.

7 2020 at 718 am. Long term Fate Therapeutics stock forecast for 2022 2023 1 year - 2025 - 2027 5 year - 2030 and 2032 10 year Forecast for 2022 Apr. 47 rows Close price at the end of the last trading day Friday 6th May 2022 of.

On average analysts give the stock a Strong Buy rating. FATE Fate Therapeutics Inc. Ad How this fund did well in bull and bear markets.

On average they anticipate Fate Therapeutics. In the last 3 months 4 analysts have offered 12-month price targets for Fate Therapeutics. The company has an average price target of 9325 with a high of 12200 and.

Fate Therapeutics Stock Forecast 05-03-2022. 5 Wall Street analysts that have issued a 1 year FATE price target the average FATE price target is 9360 with the highest FATE stock price forecast at 11500 and the. 1y Target Est 8626 Fair Value is the appropriate price for the shares of a company based on its earnings and growth rate also interpreted as when PE Ratio Growth Rate.

According to the issued ratings of 9 analysts in the last year the consensus rating for Fate Therapeutics stock is Buy based on the current 2 hold ratings and 7 buy ratings for. 9 brokerages have issued twelve-month price targets for Fate Therapeutics shares. FATE has a greater upside potential average analyst target price relative to current price than 149379 of stocks in the mid market cap category.

How this fund beats the SP in bull and bear markets. Stock Price Forecast The 19 analysts offering 12-month price forecasts for Fate Therapeutics Inc have a median target of 9000 with a high estimate of 13500 and a low estimate of 4200. Fate Therapeutics stock forecasts are adjusted once a day.

Over the past 96 months FATEs priceearnings ratio has gone down 256. Their forecasts range from 6000 to 11600. Is 1761 for 2026.

A rare market phenomena could change everything and theres no telling when it will occur. Fate Therapeutics Inc. 2075 -069 -324 As of 1054AM.

Fate Therapeutics stock price target raised to 88 from 55 at Wedbush Dec. Negative dynamics for Fate Therapeutics shares will prevail with possible. The average price target is 103866 which means analysts.

This price target is based on 10 analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. ET by Tomi Kilgore Fate Therapeutics stock price target raised to 65 from 40 at Truist. Is a clinical-stage biopharmaceutical company.

The average price target is 9300 with a high forecast of 14500 and a. 65 Day Avg Vol 1330184. FATE stock forecast and price target.

Sign in to your SmartPortfolio to see more analyst recommendations. The average price target is 000 with a high estimate of 000 and a low estimate of 000. The Fate Therapeutics stock prediction results are shown below and presented as a graph table and text information.

According to 26 stock analysts the average 12-month stock price forecast for FATE stock is 8799 which predicts an increase of 26329.

Fate Therapeutics Jumped On Supportive Trial Data Nasdaq Fate Seeking Alpha